Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 6/20 | 0.44 |
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | CYP2C18 | P33260 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25417972 | 0.79 | CYP2A6 (0.46) | POLBALDH1A1HTTCYP3A4 | |
| SCHEMBL27658183 | 0.78 | ALDH1A1 (0.41) | POLBNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL10941265 | 0.75 | RAB9A (0.61) | POLBNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL6057416 | 0.74 | POLB (0.53) | POLBNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL24214812 | 0.74 | HIF1A (0.41) | RAB9ASMN1; SMN2NPSR1MAPTCYP2C9 | |
| SCHEMBL7082394 | 0.73 | POLB (0.57) | POLBNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL255499 | 0.73 | POLB (0.57) | POLBNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL5579308 | 0.73 | POLB (0.57) | POLBNPC1RAB9ALMNANPSR1 | |
| SCHEMBL411379 | 0.73 | POLB (0.57) | POLBNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL17227421 | 0.73 | POLB (0.57) | POLBNPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109662961-A | For improving the method and composition of cognitive function | 约翰斯霍普金斯大学 | 2019-04-23 | — | — | CN | disclosed |
| CN-109662964-A | For improving the method and composition of cognitive function | 约翰斯.霍普金斯大学 | 2019-04-23 | — | — | CN | disclosed |
| CN-107567452-A | Imidazopyrazine and pyrazolopyrimidine and their purposes as ampa receptor conditioning agent | 詹森药业有限公司 | 2018-01-09 | — | — | CN | disclosed |
| CN-105899509-B | Isopropyl triazolopyridine compounds | 伊莱利利公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-102947303-B | Bicyclo-pyridyl pyrazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-12-14 | — | — | CN | disclosed |
| CN-105142623-A | Methods and compositions for improving cognitive function | AGENEBIO INC | 2015-12-09 | — | — | CN | disclosed |
| US-9187454-B2 | Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof | BOSTON BIOMEDICAL, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187454-B2 | Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof | BOSTON BIOMEDICAL, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140275033-A1 | INHIBITORS OF KINASES AND CANCER STEM CELLS, AND METHODS OF PREPARATION AND USE THEREOF | BOSTON BIOMEDICAL, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275033-A1 | INHIBITORS OF KINASES AND CANCER STEM CELLS, AND METHODS OF PREPARATION AND USE THEREOF | BOSTON BIOMEDICAL, INC. | 2014-09-18 | — | — | US | disclosed |
| CN-104039785-A | Heterocyclylpyrazoles as fungicides | BAYER IP GMBH | 2014-09-10 | — | — | CN | disclosed |
| CN-103476255-A | Methods and compositions for improving cognitive function | UNIV JOHNS HOPKINS | 2013-12-25 | — | — | CN | disclosed |
| CN-103360364-A | Synthetic method of aromatic cyclo-ethanol | QIU YIBIN | 2013-10-23 | — | — | CN | disclosed |
| CN-102905532-A | Methods and compositions for improving cognitive function | UNIV JOHNS HOPKINS | 2013-01-30 | — | — | CN | disclosed |
| CN-101365700-A | Azaindazoles useful as inhibitors of kinases | VERTEX PHARMA (US) | 2009-02-11 | — | — | CN | disclosed |
| EP-1812450-A2 | TGF-BETA INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006052568-A2 | TGF-BETA INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275033-A1 | INHIBITORS OF KINASES AND CANCER STEM CELLS, AND METHODS OF PREPARATION AND USE THEREOF | MAP3K1, MAP3K6, MAP3K9 | POLB 1741/4885NPC1 3118/4885RAB9A 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.